From: Overcoming multiple drug resistance mechanisms in medulloblastoma
Cell line | IC50TMZ | IC50TMZ + Rucaparib | PF | IC50Propargyl | IC50Propargyl + Rucaparib | PF |
---|---|---|---|---|---|---|
DAOY | 540 ± 70.2 | 253 ± 35.1 | 1.9* | 68.3 ± 26.2 | 47.9 ± 4.6 | 1.4 |
MED1 | 31 ± 12.4 | 26.8 ± 10.9 | 1.2 | 42.2 ± 9.5 | 43.4 ± 14 | 1.0 |
UW228-3 | 290 ± 14.8 | 129.5 ± 12 | 2.2* | 96.3 ± 21.2 | 94.3 ± 38 | 1.0 |
MED3 | 332.9 ± 81.8 | 124.7 ± 55.3 | 2.7** | 53.6 ± 16.8 | 56.3 ± 26.6 | 1.0 |